March 21, 2019
Phase 2 data for from the Believe-PV study for PRN1008 show that the investigational agent from Principia Biopharma reached the primary efficacy measure in pemphigus. Data confirm that Sebacia microparticles confer benefit in the management of acne vulgaris in real-world settings. Candela has rebranded to reflect the unification of the Syneron and Candela brands. Dupixent from Regeneron Pharmaceuticals and Sanofi is now approved to treat atopic dermatitis in patients ages 12 through 17.